Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | PRF1 | P14222 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768766 | 0.84 | BRPF1 (0.44) | MAPTSIRT6BRPF1TP53THRB | |
| SCHEMBL6909940 | 0.76 | PIK3CG (0.46) | CYP11B2SIRT6SIGMAR1DYRK1A | |
| SCHEMBL748257 | 0.76 | CYP19A1 (0.40) | CYP11B2MAPTSIRT6PIK3CASIGMAR1 | |
| SCHEMBL782548 | 0.76 | CYP11B2 (0.48) | CYP11B2BRPF1BRD4 | |
| SCHEMBL31260108 | 0.72 | CYP11B1 (0.59) | CYP11B2 | |
| SCHEMBL14792305 | 0.72 | CYP11B1 (0.59) | CYP11B2 | |
| SCHEMBL31149505 | 0.72 | CYP11B2 (0.43) | CYP11B2MAPTSIRT6TP53THRB | |
| SCHEMBL746136 | 0.72 | SIRT6 (0.49) | CYP11B2SIRT6PIK3CA | |
| SCHEMBL782798 | 0.71 | CYP11B2 (0.43) | CYP11B2BRPF1BRD4 | |
| SCHEMBL10233229 | 0.70 | PDE10A (0.43) | CYP11B2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459223-B | 5-pyridin-3-yl-1, 3-dihydro-indol-2-one derivatives and their use as aldosterone synthase and/or CYP11B1 modulators | NOVARTIS AG | 2014-11-05 | — | — | CN | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| CN-102459223-A | 5-pyridin-3-yl-1, 3-dihydro-indol-2-one derivatives and their use as aldosterone synthase and/or CYP11B1 modulators | NOVARTIS AG | 2012-05-16 | — | — | CN | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | CYP11B2 1/4885MAPT 1619/4885SIRT6 2458/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | CYP11B2 3/4885MAPT 2075/4885SIRT6 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.